FindTrial
Sign In

Treatment effects of apremilast for Behcet's disease: a systematic review and meta-analysis

Treatment effects of apremilast for Behcet's disease: a systematic review and meta-analysis - Treatment effects of apremilast for Behcet's disease: a systematic review and meta-analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000044257
Enrollment
Unknown
Registered
2021-05-19
Start date
2021-05-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behcet&#39

Interventions

None listed

Sponsors

Yokohama City University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Behcet's disease patients treated with apremilast

Exclusion criteria

Exclusion criteria: Patients not fulfilled Behcet's disease diagnostic criteria

Design outcomes

Primary

MeasureTime frame
BDCAF and presence of BD-related symptoms after 12 weeks of apremilast treatment—

Countries

Japan

Contacts

Public ContactKaoru Minegishi

Yokohama City University School of Medicine Department of Stem Cell and Immune Regulation

kaoru-t@yokohama-cu.ac.jp0457872800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026